Skip to main content
Caplight Logo









AaviGen

AaviGen

Private
HeidelbergHealthcare & Life Scienceshttps://aavigen.com/

Last Round

Accelerator

Jun 4, 2025

Total Funding Raised

$18.85M

Company Overview

AaviGen is a biotechnology company that develops precision gene therapies for cardiovascular and cardiopulmonary diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

gene therapycardiovascular gene therapyAdeno-Associated Viral vectorsAAV vectorsAAV vector engineeringcardiac-specific AAVheart failure therapyAAV capsidsvector discoverygene deliverypreclinical biotechnologycardiopulmonary diseasedual-organ AAV capsidscontract development and manufacturing organizationCDMO

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AaviGen Comparables

Compare AaviGen with similar companies based on industry and business-model similarity.

AaviGen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Affinia Therapeutics
80%
Medera
78%
Medley Therapeutics, Inc.
77%

AaviGen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorJun 4, 2025
Series BJul 26, 2023

AaviGen Investors

Notable investors and investment history

AaviGen investors
InvestorRounds
dievini Hopp BioTech holdingSeries B
German AcceleratorAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 4, 2025

    Received funding from German Accelerator.

  • Jul 26, 2023

    $19M round led by DH-LT Investments GmbH.

AaviGen Filings

Explore SEC and related filing metadata, where available.

AaviGen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AaviGen's valuation, stock price, and market status.

Is AaviGen a public or private company?

AaviGen is a private company.

What is the current stock price of AaviGen?

AaviGen is a private company with no public stock price. No recent secondary market data is available.

How much is AaviGen worth (valuation)?

Valuation information for AaviGen is not publicly available.

Can I buy AaviGen stock?

AaviGen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AaviGen's last funding round?

AaviGen's most recent funding round was Accelerator on June 4, 2025.

Who are the main investors in AaviGen?

Key investors in AaviGen include dievini Hopp BioTech holding.

Will AaviGen IPO soon?

No public IPO plans have been announced for AaviGen.

How can I track AaviGen secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AaviGen's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHeidelberg
Year Founded2019
Last FundingJun 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?